Allogene Therapeutics Inc (NASDAQ:ALLO) finished Friday with a subtraction of -$0.24 to close at $3.17, a downside of -7.04 percent. An average of 1,567,300 shares of common stock have been traded in the last five days. There was a fall of -$0.48 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 1,779,110 shares traded, while the 50-day average volume stands at 1,857,916.
ALLO stock has decreased by -19.95% in the last month. The company shares reached their 1-month lowest point of $3.08 on 09/29/23. With the stock rallying to its 52-week high on 01/27/23, shares of the company touched a low of $3.28 and a high of $12.21 in 52 weeks. It has reached a new high 7 times so far this year and lost -49.60% or -$3.12 in price. In spite of this, the price is down -74.04% from the 52-week high.
Insider Transactions
ALLO stock investors should be aware that Allogene Therapeutics Inc (ALLO) stock had its last reported insider trading activity 54 days ago on Aug 07. In this transaction, the insider spent $42,855. General Counsel, Bhavnagri Veer, disposed of 3,000 shares at a price of $6.85 on Feb 13. The insider now owns more than $20,550 worth of shares. Prior to that, General Counsel Bhavnagri Veer went on to Sale 3,000 shares at $7.04 each on Jan 17. An amount of $21,120 was transacted.
Valuation Metrics
Allogene Therapeutics Inc (ALLO) stock’s beta is 0.79. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2796.77, the price-to-book (PB) ratio at 0.85.
Financial Health
The quick ratio of Allogene Therapeutics Inc for the three months ended June 29 was 9.18, and the current ratio was 9.18, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.15 and a total debt to equity ratio of 0.16 for the quarter ending June 29. Its gross profit as reported stood at $335.69 million compared to revenue of $0.24 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$77.99 million in the quarter, while revenues of -$98.7 million were grew 4.1%. The analyst consensus anticipated Allogene Therapeutics Inc’s latest quarter earnings to come in at -$0.59 per share, but it turned out to be -$0.53, a 10.20% surprise. For the quarter, EBITDA amounted to -$77.95 million. Shareholders own equity worth $167.63 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Allogene Therapeutics Inc (ALLO) price momentum. RSI 9-day as of the close on 29 September was 19.41%, suggesting the stock is oversold, with historical volatility in this time frame at 36.97%.
As of today, ALLO’s price is $3.37 -13.15% or -$0.48 from its 5-day moving average. ALLO is currently trading -18.51% lower than its 20-day SMA and -49.84% lower than its 100-day SMA. However, the stock’s current price level is -39.96% below the SMA50 and -60.62% below the SMA200.
The stochastic %K and %D were 8.05% and 8.19%, respectively, and the average true range (ATR) was 0.21. With the 14-day stochastic at 7.88% and the average true range at 0.22, the RSI (14) stands at 26.15%. The stock has reached -0.22 on the 9-day MACD Oscillator while the 14-day reading was at -0.37.
